IP Library Granted Patent US 11,724,987
Granted Patent B2
US 11,724,987 · App. 17/164,556 · Granted Aug 15, 2023

Compositions and methods of treating retinal disease

Inventors: Thomas A. Jordan (Lexington, MA); John E. Dowling (Boston, MA); John Clifford Chabala (Scotch Plains, NJ)
Assignee: Aldeyra Therapeutics, Inc.
C07D215/38A61K31/41A61K31/423A61K31/426A61K31/435A61K31/44A61K31/4418A61K31/47A61K31/4706C07C215/68C07C229/56C07C229/60C07D261/06C07D275/00C07D277/40C07D277/56C07D333/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,724,987
App. No.
17/164,556
Granted
Aug 15, 2023
Kind
B2
Abstract

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Claims (10)

1. A method of treating macular degeneration in a subject, the method comprising administering to the subject a compound of the following structure:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the macular degeneration is age related macular degeneration (AMD).

3. The method of claim 2 , wherein the AMD is wet AMD.

4. The method of claim 2 , wherein the AMD is dry AMD.

5. The method of claim 1 , wherein the macular degeneration is Stargardt's disease.

6. The method of claim 1 , wherein the compound is administered topically to the eye of the subject.

7. The method of claim 1 , wherein the compound is administered as an eye-drop or ophthalmic ointment.

8. The method of claim 1 , wherein the compound is administered by intraocular injection.

9. The method of claim 8 , wherein the compound is

Assignments (4)
CHANGE OF ADDRESS Recorded Feb 13, 2021
From: NEURON SYSTEMS, INC.
To: NEURON SYSTEMS, INC.
Reel/Frame 056110/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2021
From: JORDAN, THOMAS A.; DOWLING, JOHN E.; CHABALA, JOHN CLIFFORD
To: NEURON SYSTEMS, INC.
Reel/Frame 055251/0541 →
CHANGE OF NAME Recorded Feb 13, 2021
From: NEURON SYSTEMS, INC.
To: ALDEXA THERAPEUTICS, INC.
Reel/Frame 055301/0444 →
CHANGE OF NAME Recorded Feb 13, 2021
From: ALDEXA THERAPEUTICS, INC.
To: ALDEYRA THERAPEUTICS, INC.
Reel/Frame 055301/0457 →
Continuity (10)
Continuation 16241851 · Jan 7, 2019
Continuation 15861332 · Jan 3, 2018
Continuation 15488205 · Apr 14, 2017
Continuation 15049890 · Feb 22, 2016
Continuation 14581462 · Dec 23, 2014
Continuation 13175218 · Jul 1, 2011
Continuation 11441848 · May 26, 2006
Provisional Application 60723577 · Oct 4, 2005
Provisional Application 60685460 · May 26, 2005
Related Publication 20210269402A1 · Sep 2, 2021
Cited By (1)
US 12,240,816